COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
12/05/2025
TARPON SPRINGS, Fla., May 12, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual [...]
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee (DSMC)
12/05/2025
DSMC concluded that Phase 1 study may continue as planned without any modifications On track to complete the enrollment of the first two cohorts by mid-2025 SYDNEY, May 12, 2025 (GLOBE NEWSWIRE) -- Radiopharm [...]
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences
12/05/2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
ArriVent BioPharma Reports First Quarter 2025 Financial Results
12/05/2025
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC [...]
Glass House Brands to Hold Investor Sesh IV on Friday, June 20th
12/05/2025
We are excited to continue our tradition of hosting this unique cannabis industry event, providing transparency and expressing gratitude to our loyal shareholders LONG BEACH, Calif. and TORONTO, May 12, 2025 (GLOBE [...]
Foresight Diagnostics to Participate in the Jefferies Global Healthcare Conference
12/05/2025
BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today [...]
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
12/05/2025
Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash [...]
IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products
12/05/2025
Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. [...]
ORYZON Reports Financial Results and Corporate Update for Quarter Ended March 31, 2025
12/05/2025
Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European [...]
Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference
12/05/2025
LEXINGTON, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a [...]
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
12/05/2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today [...]
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
12/05/2025
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today [...]
IMUNON Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2 OVATION 2 study of IMNN-001 accepted for oral presentation at 2025 ASCO Annual [...]
Belite Bio to Participate in Four Upcoming Investor Conferences
12/05/2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases [...]
Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation
12/05/2025
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ). As the biopharma industry faces increasing competition from international markets and an evolving [...]
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
12/05/2025
Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate [...]
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
12/05/2025
FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden [...]
Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
12/05/2025
RESEARCH TRIANGLE PARK, N.C., May 12, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) [...]
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
12/05/2025
Data presentation included efficacy and biomarker analyses from the NAVIGATE trial (n=287). Belapectin 2 mg/kg demonstrated a statistically significant reduction in new varices at 18 months in the per-protocol [...]

Pages